Home Alzheimer’s Disease FDA Approves Olaparib for HRR Gene-Mutated mCRPC

FDA Approves Olaparib for HRR Gene-Mutated mCRPC

The FDA has approved olaparib (Lynparza) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide (Xtandi) or abiraterone (Zytiga), according to AstraZeneca and Merck, the joint developers of the agent.

The FDA recommended a dose of 300 mg of olaparib, taken orally twice daily, with or without food. 

“Prostate cancer has lagged behind other solid tumors in the era of precision medicine,” Maha Hussain, MD, one of the principle investigators of the trial and deputy director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, said in a press release. “I am thrilled by the approval of (olaparib), which now brings a molecularly targeted…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments